{"denoms":[{"counts":[{"groupId":"BG000","value":"133"},{"groupId":"BG001","value":"133"},{"groupId":"BG002","value":"133"},{"groupId":"BG003","value":"399"}],"units":"Participants"}],"groups":[{"description":"Patients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.","id":"BG000","title":"Canakinumab, Pre-filled Syringes (PFS)"},{"description":"The patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized power and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.","id":"BG001","title":"Canakinumab, Lyophilizate (LYO)"},{"description":"The patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.","id":"BG002","title":"Triamcinolone Acetonide"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.21","value":"53.4"},{"groupId":"BG001","spread":"11.84","value":"53"},{"groupId":"BG002","spread":"11.33","value":"53.7"},{"groupId":"BG003","spread":"11.44","value":"53.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"35"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"122"},{"groupId":"BG003","value":"364"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}